FibroBiologics (NASDAQ: FBLG) exits Webster lease early, eyeing $0.8M savings

Q: How much rent does FibroBiologics (FBLG) expect to save from terminating its sublease?

FibroBiologics expects to save approximately $0.8 million in future rent. The company ended its Webster, Texas sublease early by making a single payment, eliminating redundant office costs and consolidating operations into its newer facility.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

8-K/A

Rhea-AI Filing Summary

FibroBiologics, Inc. filed an amended current report to correct an omitted item number, without changing any prior disclosures. The company highlights a Sublease Buyout Agreement that ended its Webster, Texas sublease effective April 2, 2026, ahead of the original November 30, 2027 expiration.

FibroBiologics resolved all remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent. This move follows the 2025 opening of a new laboratory facility with over 10,000 square feet of lab and office space and supports consolidating operations. The company also updates its principal executive office address to 9350 Kirby Drive, Suite 300, Houston, Texas 77054.

8-K Event Classification

4 items: 1.01, 1.02, 8.01, 9.01

4 items

Item 1.01 Entry into a Material Definitive Agreement Business

The company signed a significant contract such as a merger agreement, credit facility, or major partnership.

Item 1.02 Termination of a Material Definitive Agreement Business

A significant contract was terminated, which may affect business operations or revenue.

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Lease buyout payment: $45,108.25 Expected rent savings: approximately $0.8 million Original sublease end date: November 30, 2027 +3 more

6 metrics

Lease buyout payment $45,108.25 Single payment to resolve remaining rent obligations on sublease

Expected rent savings approximately $0.8 million Future rent savings from early termination of Webster sublease

Original sublease end date November 30, 2027 Initial expiration of Webster, Texas sublease before buyout

Sublease termination effective date April 2, 2026 Date the Lease Termination Agreement ended the sublease

New lab and office size over 10,000 square feet Size of state-of-the-art laboratory facility opened in 2025

New principal office address 9350 Kirby Drive, Suite 300, Houston, TX 77054 Updated location for company’s principal executive offices

Key Terms

Material Definitive Agreement, Sublease Buyout Agreement, Lease Termination Agreement, emerging growth company, +1 more

5 terms

Material Definitive Agreement regulatory

"Item 1.01 Entry into a Material Definitive Agreement."

A material definitive agreement is a legally binding contract that creates major, long‑term obligations or rights for a company, such as loans, asset sales, mergers, or supplier deals. Think of it like a mortgage or lease for a business: it can change future cash flow, risk and control, so investors watch these agreements closely because they can materially affect a company’s value, financial health and stock price.

Sublease Buyout Agreement financial

"entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”)"

Lease Termination Agreement financial

"Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co."

emerging growth company regulatory

"Emerging growth company Explanatory Note"

An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.

principal executive offices financial

"The new address of the Company’s principal executive offices is 9350 Kirby Drive"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Understanding 8-K Material Events →

04/09/2026 - 05:20 PM

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K/A

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     Date of Report (Date of earliest event reported): April 03, 2026

    

FibroBiologics, Inc.

(Exact name of Registrant as Specified in Its Charter)


Delaware	001-41934	86-3329066
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

9350 Kirby Drive, Suite 300
Houston, Texas		77054
(Address of Principal Executive Offices)		(Zip Code)

     Registrant’s Telephone Number, Including Area Code: 281 671-5150

    

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.00001 par value	FBLG	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Explanatory Note

This Amendment to the Current Report on Form 8-K filed by FibroBiologics, Inc. (the "Company") on April 9, 2026 (the "Original Report") is being filed to include an additional item number that was inadvertently omitted in the Original Report (Item 1.02 should have been included along with Item 1.01). The Company is amending the Original Report for the sole purpose of including the new item. No disclosure has changed from the Original Report.

Item 1.01 Entry into a Material Definitive Agreement.

On April 3, 2026, FibroBiologics, Inc. (the “Company”) entered into a Sublease Buyout Agreement (the “Lease Termination Agreement”) with United Fire & Casualty Co. (doing business as United Fire Group) (the “Sublandlord”) to terminate that certain Sublease Agreement, which was effective as of October 5, 2022 (“Sublease”), pursuant to which Sublandlord subleased to the Company certain premises located at the third floor of 455 E. Medical Center Blvd, Webster, County of Harris, Texas 77598. The Lease Termination Agreement terminated the Sublease effective April 2, 2026, successfully concluding the Sublease well ahead of its original expiration date of November 30, 2027. The Company resolved its remaining rent obligations with a single payment of $45,108.25 and expects to save approximately $0.8 million in future rent payments.

This strategic consolidation follows the Company's 2025 opening of its state-of-the-art laboratory facility, encompassing over 10,000 square feet of dedicated lab and office space. By eliminating redundant office costs approximately 18 months ahead of schedule, the Company strengthens its operational efficiency and redirects resources toward its core mission of advancing fibroblast-based therapeutics.

Item 1.02 Termination of a Material Definitive Agreement.

The information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated into this Item 1.02 by reference.

Item 8.01 Other Events.

The new address of the Company’s principal executive offices is 9350 Kirby Drive, Suite 300, Houston, Texas 77054.

Item 9.01 Financial Statements and Exhibits.


Exhibit 104		Cover Page Interactive Data File (embedded within the inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			FibroBiologics, Inc.

Date:	Apri 9, 2026	By:	/s/ Pete O'Heeron
			Name: Pete O'Heeron Title: Chief Executive Officer

Source: View Original Filing on SEC EDGAR

FAQ

What is FibroBiologics (FBLG) changing in this amended 8-K filing?

FibroBiologics is amending a prior report solely to add Item 1.02, which was inadvertently omitted. The underlying disclosures stay the same, focusing on a lease termination and updated company address.

How much rent does FibroBiologics (FBLG) expect to save from terminating its sublease?

FibroBiologics expects to save approximately $0.8 million in future rent. The company ended its Webster, Texas sublease early by making a single payment, eliminating redundant office costs and consolidating operations into its newer facility.

What did FibroBiologics (FBLG) pay to exit the Webster, Texas sublease early?

FibroBiologics resolved its remaining rent obligations with a one-time payment of $45,108.25. In return, the sublease, originally expiring November 30, 2027, was terminated effective April 2, 2026, significantly ahead of schedule.

Where are FibroBiologics (FBLG) principal executive offices now located?

FibroBiologics’ principal executive offices are now at 9350 Kirby Drive, Suite 300, Houston, Texas 77054. This new address reflects the company’s consolidation around its more modern laboratory and office facility opened in 2025.

What agreement did FibroBiologics (FBLG) terminate with United Fire & Casualty?

FibroBiologics entered into a Sublease Buyout Agreement, called the Lease Termination Agreement, with United Fire & Casualty Co. It ended the sublease for premises at 455 E. Medical Center Blvd, Webster, Texas, effective April 2, 2026.

How does the lease termination relate to FibroBiologics (FBLG) new lab facility?

The lease termination follows FibroBiologics’ 2025 opening of a state-of-the-art lab facility with over 10,000 square feet. By ending the older Webster sublease, the company removes redundancy and focuses resources on this newer consolidated site.

Filing Exhibits & Attachments

1 document